Robotic surgery effective but costly in bladder cancer

Share this article:

Robotic-assisted laparoscopic radical cystectomy (RARC) is associated with lower parenteral nutrition use and fewer inpatient complications and deaths compared with the more invasive approach of open radical cystectomy (ORC), but lengths of stay are similar for both operations and RARC is significantly more costly.

These were the findings of a retrospective observational cohort study using the US Nationwide Inpatient Sample to compare inpatient morbidity and mortality, lengths of stay, and costs for RARC and ORC. A group led by Jim C. Hu, MD, MPH, director of minimally invasive urology at the David Geffen School of Medicine at University of California, Los Angeles, identified 1,444 ORC cases and 224 RARC cases, with women being less likely to undergo RARC than ORC (9.8% vs 15.5%).

The investigators learned the following:

  • Persons undergoing RARC experienced fewer inpatient complications than those undergoing ORC (49.1% compared with 63.8%). However, there were no differences in lengths of stay between the two groups.
  • Parenteral nutrition use was lower in the RARC group than in the ORC group (6.4% vs 13.3%).
  • Deaths were less likely to occur in the RARC group than in the ORC group (0% vs 2.5%).
  • RARC cost $3,797 more than ORC.

“While we expected to see greater expenses associated with the robotic procedure for bladder cancer, we were surprised to see the significant reduction in deaths and complications,” noted Hu in a statement describing his team's findings, which were published by European Urology.

As Hu's team noted in their report, their research was limited by its retrospective design, an absence of data on tumor characteristics, and a lack of outcomes data beyond hospital discharge.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Y-90 radioembolization: A new treatment for hepatic metastases from breast cancer

Yttrium-90 radioembolization is a minimally invasive treatment that may slow disease progression in breast cancer that has metastasized to the liver.

More sensitive testing may better define prognosis and treatment for leukemia

Nearly half of patients with the most common form of adult leukemia may have a distinct pattern of genetic abnormalities that could better define their prognosis and treatment.

Doxorubicin-ifosfamide combo improves progression-free survival in soft-tissue sarcoma

A new European study does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma.